ArticlePreventive medicine reports2026
Initial outcomes of a municipality-led prostate cancer screening program: Analysis of the osaka city system in a community clinic setting.
Article in Preventive medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In Japan, prostate cancer screening is primarily conducted under municipal administration. In 2021, Osaka City, Japan, launched a publicly funded program for prostate-specific antigen (PSA) testing. This study analyzed participation trends and referral rates in a community clinic, descriptively reporting early program implementation. Methods: This retrospective observational study was conducted at a community clinic in Osaka City, Japan. Sixty men who underwent Osaka City's prostate cancer screening at our clinic between fiscal years 2021 and 2025 were included. Age-specific PSA cut-off values defined by the municipal program were applied. Changes in the number of examinees over time were descriptively summarized. Results: The numbers of participants were 5 in 2021, 6 in 2022, 20 in 2023, 23 in 2024, and 6 in 2025. Five men (8.3%) required further examination; one case was diagnosed with prostate cancer, and four had benign conditions. Conclusions: This single-center descriptive study provides clinic-level data on the early implementation of a municipality-led prostate cancer screening program in Japan and may inform future evaluations and policy discussions regarding municipal screening initiatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.